Diffusion-weighted MRI of estrogen receptor-positive, HER2-negative, node-negative breast cancer: association between intratumoral heterogeneity and recurrence risk

被引:36
|
作者
Kim, Jin You [1 ,2 ]
Kim, Jin Joo [1 ]
Hwangbo, Lee [1 ]
Lee, Ji Won [1 ]
Lee, Nam Kyung [1 ]
Nam, Kyung Jin [3 ]
Choo, Ki Seok [3 ]
Kang, Taewoo [4 ]
Park, Heeseung [4 ]
Son, Yohan [5 ]
Grimm, Robert [6 ]
机构
[1] Pusan Natl Univ Hosp, Med Res Inst, Dept Radiol, Busan, South Korea
[2] Pusan Natl Univ, Dept Radiol, Sch Med, 1-10 Ami Dong, Busan 602739, South Korea
[3] Pusan Natl Univ, Dept Radiol, Yangsan Hosp, Yangsan, South Korea
[4] Pusan Natl Univ Hosp, Busan Canc Ctr, Busan, South Korea
[5] Siemens Healthineers Ltd, Seoul, South Korea
[6] Siemens Healthcare GmbH, Erlangen, Germany
关键词
Diffusion magnetic resonance imaging; Breast neoplasms; Oncotype DX; Recurrence; Biomarkers; ADJUVANT SYSTEMIC THERAPY; ONCOTYPE-DX; AMERICAN-SOCIETY; EARLY-STAGE; TUMOR HETEROGENEITY; GENE-EXPRESSION; COEFFICIENT; CHEMOTHERAPY; WOMEN; SURVIVAL;
D O I
10.1007/s00330-019-06383-6
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objectives To investigate possible associations between quantitative apparent diffusion coefficient (ADC) metrics derived from whole-lesion histogram analysis and breast cancer recurrence risk in women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-negative breast cancer who underwent the Oncotype DX assay. Methods This retrospective study was conducted on 105 women (median age, 48 years) with ER-positive, HER2-negative, node-negative breast cancer who underwent the Oncotype DX test and preoperative diffusion-weighted imaging (DWI). Histogram analysis of pixel-based ADC data of whole tumors was performed, and various ADC histogram parameters (mean, 5th, 25th, 50th, 75th, and 95th percentiles of ADCs) were extracted. The ADC difference value (defined as the difference between the 5th and 95th percentiles of ADCs) was calculated to assess intratumoral heterogeneity. Associations between quantitative ADC metrics and the recurrence risk, stratified using the Oncotype DX recurrence score (RS), were evaluated. Results Whole-lesion histogram analysis showed that the ADC difference value was different between the low-risk recurrence (RS < 18) and the non-low-risk recurrence (RS >= 18; intermediate to high risk of recurrence) groups (0.600 x 10(-3) mm(2)/s vs. 0.746 x 10(-3) mm(2)/s, p < 0.001). Multivariate regression analysis demonstrated that a lower ADC difference value (< 0.559 x 10(-3) mm(2)/s; odds ratio [OR] = 5.998; p = 0.007) and a small tumor size (<= 2 cm; OR = 3.866; p = 0.012) were associated with a low risk of recurrence after adjusting for clinicopathological factors. Conclusions The ADC difference value derived from whole-lesion histogram analysis might serve as a quantitative DWI biomarker of the recurrence risk in women with ER-positive, HER2-negative, node-negative invasive breast cancer.
引用
收藏
页码:66 / 76
页数:11
相关论文
共 50 条
  • [21] Management of hormone receptor-positive, HER2-negative early breast cancer
    Walsh, Elaine M.
    Smith, Karen L.
    Stearns, Vered
    SEMINARS IN ONCOLOGY, 2020, 47 (04) : 187 - 200
  • [22] Impact of 21-Gene Expression Assay on Staging Estrogen Receptor-Positive HER2-Negative Breast Cancer
    Breaux, Andrea
    Turner, Bradley
    Wu, Xiaoyong
    Rai, Shesh N.
    Riley, Elizabeth C.
    Mandadi, Mounika
    Sanders, Mary Ann
    CLINICAL BREAST CANCER, 2019, 19 (01) : E261 - E269
  • [23] Risk of Recurrence and Chemotherapy Benefit for Patients With Node-Negative, Estrogen Receptor-Positive Breast Cancer: Recurrence Score Alone and Integrated With Pathologic and Clinical Factors
    Tang, Gong
    Cuzick, Jack
    Costantino, Joseph P.
    Dowsett, Mitch
    Forbes, John F.
    Crager, Michael
    Mamounas, Eleftherios P.
    Shak, Steven
    Wolmark, Norman
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (33) : 4365 - 4372
  • [24] Multicenter retrospective study on the use of Curebest™ 95GC Breast for estrogen receptor-positive and node-negative early breast cancer
    Tsukamoto, Fumine
    Arihiro, Koji
    Takahashi, Mina
    Ito, Ken-ichi
    Ohsumi, Shozo
    Takashima, Seiki
    Oba, Takaaki
    Yoshida, Masayuki
    Kishi, Kazuki
    Yamagishi, Keisuke
    Kinoshita, Takayuki
    BMC CANCER, 2021, 21 (01)
  • [25] The Utility of Oncotype DX for Adjuvant Chemotherapy Treatment Decisions in Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative, Node-negative Breast Cancer
    Rizki, Hirah
    Hillyar, Christopher
    Abbassi, Omar
    Miles-Dua, Sascha
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (03)
  • [26] Factors That Predict Biological Aggressiveness in Estrogen Receptor-Positive / Human Epidermal Growth Factor Receptor 2-Negative / Lymph Node-Negative Breast Cancer
    Arthur, Lauren E.
    McMann, Ashley H.
    Slattery, Lauren N.
    Fuhrman, George M.
    Mackey, Aimee M.
    Rivere, Amy E.
    Corsetti, Ralph L.
    OCHSNER JOURNAL, 2020, 20 (04) : 381 - 387
  • [27] Intratumoral heterogeneity of Ki67 proliferation index outperforms conventional immunohistochemistry prognostic factors in estrogen receptor-positive HER2-negative breast cancer
    Zilenaite-Petrulaitiene, Dovile
    Rasmusson, Allan
    Besusparis, Justinas
    Valkiuniene, Ruta Barbora
    Augulis, Renaldas
    Laurinaviciene, Aida
    Plancoulaine, Benoit
    Petkevicius, Linas
    Laurinavicius, Arvydas
    VIRCHOWS ARCHIV, 2025, 486 (02) : 287 - 298
  • [28] Molecular classification of hormone receptor-positive HER2-negative breast cancer
    Jin, Xi
    Zhou, Yi-Fan
    Ma, Ding
    Zhao, Shen
    Lin, Cai-Jin
    Xiao, Yi
    Fu, Tong
    Liu, Cheng-Lin
    Chen, Yi-Yu
    Xiao, Wen-Xuan
    Liu, Ya-Qing
    Chen, Qing-Wang
    Yu, Ying
    Shi, Le-Ming
    Shi, Jin-Xiu
    Huang, Wei
    Robertson, John F. R.
    Jiang, Yi-Zhou
    Shao, Zhi-Ming
    NATURE GENETICS, 2023, 55 (10) : 1696 - +
  • [29] Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer
    Poorvu, Philip D.
    Gelber, Shari, I
    Rosenberg, Shoshana M.
    Ruddy, Kathryn J.
    Tamimi, Rulla M.
    Collins, Laura C.
    Peppercorn, Jeffrey
    Schapira, Lidia
    Borges, Virginia F.
    Come, Steven E.
    Warner, Ellen
    Jakubowski, Debbie M.
    Russell, Christy
    Winer, Eric P.
    Partridge, Ann H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (07) : 725 - +
  • [30] EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
    K. Almstedt
    S. Mendoza
    M. Otto
    M. J. Battista
    J. Steetskamp
    A. S. Heimes
    S. Krajnak
    A. Poplawski
    A. Gerhold-Ay
    A. Hasenburg
    C. Denkert
    M. Schmidt
    Breast Cancer Research and Treatment, 2020, 182 : 137 - 146